Heron Therapeutics Enters Multi-Product License Agreement with Long Grove

What Happened

• Heron Therapeutics, Inc. announced in an 8-K filed Sept. 29, 2026 that it entered a multi-product Development and License Agreement effective Sept. 23, 2026 with Long Grove Pharmaceuticals, LLC and Capstone Development Services Company, LLC.
• Under the agreement Long Grove grants Heron an exclusive (as to the licensed patents), sublicensable U.S. license to import, distribute, sell and market certain products in the United States (including territories, commonwealths and possessions), and a non-exclusive worldwide manufacturing license for products sold in the U.S. Capstone participates solely to provide exclusivity covenants and backstop obligations.
• The agreement requires Heron to pay regulatory and sales-based milestone payments, royalties and reimburse certain expenses; full agreement text will be filed as an exhibit to Heron’s Form 10‑Q for the quarter ending Sept. 30, 2026.

Key Details

• Effective date: September 23, 2026; 8‑K filed September 29, 2026.
• License scope: exclusive U.S. commercial rights (as to licensed patents), sublicensable; non-exclusive manufacturing rights worldwide for Territory sales.
• Payments: regulatory milestones, sales-based milestones, royalty payments, and reimbursement of certain expenses (specific dollar amounts not disclosed in the 8‑K).
• Term: initial 10-year term after first commercial sale, with automatic two-year renewal terms; termination rights are customary for this type of agreement.

Why It Matters

• This deal potentially expands Heron’s U.S. commercial product portfolio and creates new revenue opportunities through product sales and sublicensing.
• The agreement also creates ongoing obligations (milestones, royalties, reimbursements) that could affect future margins and cash flow; financial impact depends on undisclosed payment amounts and commercial success.
• Investors should watch for the filed license agreement in the upcoming 10‑Q for full terms and for future regulatory or commercial milestones that would trigger payments or revenue.